Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI343 as monotherapy for the treatment of claudin18.2-positive advanced gastric/gastro-esophageal junction adenocarcinoma patients who have progressed after at least 2 lines of prior systematic treatments.